Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07142304 · ClinicalTrials.gov registry record · NA
The Lilac Device Trial
A NA study of Chemotherapy Induced Peripheral Neuropathy (CIPN), sponsored by Luminate Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 142
- Enrollment target
- 8
- Study locations
NCT07142304: Recruiting NA study of Chemotherapy Induced Peripheral Neuropathy (CIPN), sponsored by Luminate Medical.
NCT07142304 is a NA study of Chemotherapy Induced Peripheral Neuropathy (CIPN) that is actively recruiting participants, run by Luminate Medical. The registered enrollment target is 142 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07142304, a NA study of Chemotherapy Induced Peripheral Neuropathy (CIPN), is actively recruiting participants, sponsored by Luminate Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
- 8
- Study locations
Study Summary
Chemotherapy drugs, used in the treatment of cancer, have the potential of inducing peripheral neuropathy (PN) as a side effect. This side effect is commonly referred to as CIPN, or chemotherapy-induced peripheral neuropathy. The Lilac Glove and Boot devices apply a low pressure across the surface of the hands and feet, respectively, to reduce access of chemotherapy to the peripheral nerves on the hands and feet. The small amount of pressure reduces the level of chemotherapy reaching the peripheral nerves, hence increasing the likelihood of nerve preservation during treatment and thus may potentially temporarily prevent the onset of moderate to severe PN symptoms induced by chemotherapy in the hands and feet while receiving treatment
Primary Outcome
The occurrence of clinically meaningful overall CIPN symptoms is defined as an absolute increase of 5.06 or more points over baseline in the European Organisation for Research and Treatment of Cancer Quality of Life Chemotherapy Induced Peripheral Neuropathy-20 (EORTC QLQ-CIPN20) score (standardized 0 - 100 scale).
Conditions Studied
Interventions
- DEVICE Sham device
- DEVICE The Lilac Device
Study Locations (8)
Ohio
- Springfield Regional Cancer Center - Springfield
- Mercy Health St. Elizabeth Hospital - Youngstown
California
- Palomar Medical Center Poway - Poway
Florida
- Hialeah Hospital - Hialeah
Hawaii
- Hawaii Cancer Care - Honolulu
Illinois
- Hope and Healing Cancer Services - Hinsdale
Minnesota
- Health Partners Frauenshuh Cancer Center - Minneapolis
Wisconsin
- Hospital Sisters Health System - St.Vincent & St.Mary's - Green Bay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2026-10 |
| Phase | NA |
What NCT07142304 shows while recruiting
NCT07142304 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Chemotherapy Induced Peripheral Neuropathy (CIPN) appearing as the primary indexed condition, and to 2 interventions - of which Sham device is the first listed.
NCT07142304 lists 8 locations in 7 states (Ohio, California, Florida).
Frequently Asked Questions
What is clinical trial NCT07142304 about?
NCT07142304 is a clinical study titled "The Lilac Device Trial". Chemotherapy drugs, used in the treatment of cancer, have the potential of inducing peripheral neuropathy (PN) as a side effect. This side effect is commonly referred to as CIPN, or chemotherapy-induced peripheral neuropathy. The Lilac Glove and Boot devices apply a low pressure across the surface ...
What is the current status of trial NCT07142304?
This trial is currently recruiting. It is a NA study. The enrollment target is 142 participants. The study started on 2025-10-03. Estimated completion is 2026-10.
What conditions does trial NCT07142304 study?
This clinical trial studies the following conditions: Chemotherapy Induced Peripheral Neuropathy (CIPN).
What interventions are being tested in trial NCT07142304?
The interventions under investigation include: Sham device (DEVICE), The Lilac Device (DEVICE).
Who is sponsoring clinical trial NCT07142304?
This trial is sponsored by Luminate Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07142304 being conducted?
This trial has 8 study locations across California, Florida, Hawaii, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy Induced Peripheral Neuropathy (CIPN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07142304's enrollment target sits among peer trials
142 711th of 2000 higher than 1,289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI